Review Article

The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches

Irina Gavrilovskaya, Elena Gorbunova, Valery Matthys, Nadine Dalrymple, and Erich Mackow

Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794-5222, USA

Correspondence should be addressed to Erich Mackow, erich.mackow@stonybrook.edu

Received 27 January 2012; Revised 16 May 2012; Accepted 18 May 2012

Academic Editor: Jay Hooper

Copyright © 2012 Irina Gavrilovskaya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

American hantaviruses cause a highly lethal acute pulmonary edema termed hantavirus pulmonary syndrome (HPS). Hantaviruses nonlytically infect endothelial cells and cause dramatic changes in barrier functions of the endothelium without disrupting the endothelium. Instead hantaviruses cause changes in the function of infected endothelial cells that normally regulate fluid barrier functions of capillaries. The endothelium of arteries, veins, and lymphatic vessels is unique and central to the function of vast pulmonary capillary beds, which regulate pulmonary fluid accumulation. The endothelium maintains vascular barrier functions through a complex series of redundant receptors and signaling pathways that serve to both permit fluid and immune cell efflux into tissues and restrict tissue edema. Infection of the endothelium provides several mechanisms for hantaviruses to alter capillary permeability but also defines potential therapeutic targets for regulating acute pulmonary edema and HPS disease. Here we discuss interactions of HPS causing hantaviruses with the endothelium, potential endothelial cell-directed permeability mechanisms, and therapeutic targeting of the endothelium as a means of reducing the severity of HPS disease.

1. Introduction

Hantaviruses predominantly infect microvascular endothelial cells (ECs), which line vessels and nonlytically cause two vascular diseases: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) [1–14]. The mechanisms by which hantaviruses cause capillary leak syndromes and disrupt fluid barrier integrity of the endothelium are beginning to be disclosed and appear to involve dysregulating EC functions that normally limit fluid leakage from the vasculature [6, 15–21].

Capillaries, veins, and lymphatic vessels are lined by a single layer of ECs which collectively form one of the largest tissues of the body [22, 23]. The endothelium forms a primary fluid barrier within vessels but serves as more than just a conduit for blood to reach and return from organs [22, 24]. The endothelium selectively restricts blood and plasma from entering tissues, regulates immune cell infiltration, and responds to damage by limiting leakage, repairing vessels, and directing angiogenesis [22]. Consequently, capillary

barrier integrity is redundantly regulated by an array of EC-specific effectors that coordinately balance vascular fluid containment with tissue-specific needs and respond to a host of systemic and locally generated factors that alter inter-endothelial cell adherence junctions [22, 25–37]. ECs respond to activated platelets and immune cells, clotting cascades, chemokines and cytokines, growth factors, nitric oxide, and hypoxic conditions [22, 27, 29, 38–41]. However, ECs also secrete cytokines, complement and growth factors that positively or negatively impact the adherence and activation of platelets and immune cells, regulate responses to hypoxia, and diminish or enhance extravasation of fluid into tissues [22, 24, 26, 27, 30, 40–45]. Each of these EC responses is controlled by a diverse mesh of intertwined sensors and signals aimed at returning the endothelium to a resting state, countering permeabilizing effectors, repairing vessel damage, and restoring fluid and oxygenation levels within tissues [22, 25, 39, 41, 46–51].

The endothelium of capillaries, veins, and lymphatic vessels are unique and central to discrete functions of vast

renal and pulmonary capillary beds [42, 52–54]. Nonlytic viral infection of ECs may disengage one or more fluid barrier regulatory mechanisms, thereby increasing vascular leakage or fluid clearance and as a consequence result in tissue edema [55–60]. Although the edematous accumulation of interstitial fluids can result from increased endothelial permeability, a decrease in lymphatic vessel clearance of tissue fluids is also a cause of edema and regulated by unique lymphatic endothelial cells (LECs) [42, 53, 54, 61]. Vascular permeability induced by nonlytic viruses is likely to be multifactorial in nature, resulting from virally altered EC responses, immune cell and platelet functions, hypoxia, or a collaboration of dysregulated interactions that impact normal fluid barrier function [15–18, 20, 27, 62–64]. Failure of the endothelium to regulate fluid accumulation in tissues has pathologic consequences and during HPS results in localized vascular permeability and acute pulmonary edema that contribute to cardiopulmonary insufficiency [4–6, 9]. Here we focus on the mechanisms by which HPS causing hantavirus infection of ECs induces vascular permeability and acute edema and discuss potential therapeutic mechanisms that may stabilize the endothelium.

2. Hantavirus Infection and HPS Disease

Hantaviruses are enveloped, tripartite, negative-sense RNA viruses and form their own genus within the *Bunyaviridae* family [14, 65]. Hantaviruses are the only members of the *Bunyaviridae* that are transmitted to humans by mammalian hosts, and hantaviruses contain highly divergent RNA and protein sequences, which are likely the result of coadaptation with their hosts [13, 14, 66–68]. Single genes have been exchanged between closely related HPS causing hantaviruses [69]; however, gene reassortment has not permitted the discovery of pathogenic determinants and reverse genetics approaches have thus far proven elusive.

The hantavirus genome consists of three segments denoted S, M, and L based on the length of their RNA segments, respectively [14]. The L segment encodes the 250 kDa RNA-dependent RNA polymerase [14, 67, 70]. The S segment encodes a 48 kDa nucleocapsid (N) protein which is the most abundant hantavirus antigen present in infected cells [14, 70, 71]. The M segment encodes two viral surface glycoproteins Gn (64 kDa) and Gc (54 kDa) that are cotranslationally cleaved and targeted to the ER/cis-Golgi [14, 72]. Hantaviruses bud internally into the lumen of the cis-Golgi and exit cells via a secretory mechanism consistent with aberrant vesicular trafficking [14]. Hantaviruses are both released from ECs and remain cell associated through interactions with cell surface receptors [15, 62, 73]. GnGc heterodimers on the virion surface are presumed to bind cellular receptors and mediate viral entry into cells [14, 15, 20, 72–79].

Hantaviruses are one of only a few viruses that primarily infect the EC lining of the vasculature [8, 9, 12, 80, 81]. Hantaviruses replicate to low titers, with initial viral progeny emerging from infected ECs 18–24 hours postinfection (hpi), and $\sim 5 \times 10^6$ maximal titers days after infection [14]. Infection of ECs is nonlytic and the permeability of infected

EC monolayers is not increased by infection alone [14, 16, 82]. Prototypic HFRS (Hantaan virus-HTNV), HPS (SNV, ANDV, NY-1V) [3, 5, 10, 83, 84], and nonpathogenic (Tula virus-TULV and Prospect Hill virus-PHV) [85–87] hantaviruses all infect human ECs regardless of their ability to cause disease, suggesting that EC entry alone is not a cause of pathogenesis [12, 16, 81]. At least two requirements for hantaviruses to be pathogenic have been determined thus far, the ability of hantaviruses to regulate early interferon responses and the use of specific integrins by pathogenic (ANDV, SNV, NY-1V, PUUV, SEOV, HTNV) but not nonpathogenic (PHV, TULV) hantaviruses [20, 76, 77, 79, 88–91].

2.1. Endothelial Cell Attachment and Entry. The cellular entry of pathogenic hantaviruses is dependent on the presence of $\alpha_v\beta_3$ integrins on human ECs, while nonpathogenic hantaviruses PHV and TULV use $\alpha_5\beta_1$ integrins [76, 77]. Cells expressing recombinant $\alpha_v\beta_3$ or $\alpha_{IIb}\beta_3$ facilitate infection by SNV, NY-1V, ANDV, and HTNV, and infection is blocked by antibodies to β_3 integrins and by the β_3 integrin ligand vitronectin [62, 76]. NY-1V and ANDV bind β_3 integrins in an RGD-independent fashion via interactions with plexin-semaphorin-integrin (PSI) domains present at the apex of bent, inactive, $\alpha_v\beta_3$ integrin conformers [20, 79, 92–95]. Hantavirus binding to β_3 maintains the integrin in a resting state and inhibits EC migration on the high-affinity $\alpha_v\beta_3$ integrin ligand vitronectin [20, 62]. Infected ECs contain cell associated hantaviruses on their surface at late times post infection [15, 62, 73]. Cell associated pathogenic hantaviruses further direct the binding of quiescent platelets to the EC surface [15]. This interaction may mask hantavirus infected cells or contribute to thrombocytopenia, which is a prominent feature of hantavirus patients. Curiously, $\alpha_v\beta_3$ integrins present on ECs normally regulate vascular permeability, and inhibiting β_3 integrin functions alone causes vascular permeability disorders [41, 95–100]. Links between hantavirus dysregulation of $\alpha_v\beta_3$ functions and their role in EC permeability are discussed in detail below.

2.2. HPS Disease. At least 17 hantaviruses cause HPS, also termed hantavirus cardiopulmonary syndrome (HCPS), with prototype HPS viruses, Sin Nombre (SNV) in North America and Andes (ANDV) in South America [4–9, 101–104]. ANDV, SNV, and many closely related hantaviruses cause HPS resulting in acute pulmonary edema, cardiopulmonary insufficiency, and ~ 35 –40% mortality rates [4–9, 13, 101–103, 105–109]. One to two weeks after infection, there is a rapid onset of pulmonary edema and hypoxia that occurs 6–12 hours after cough and rapidly progresses in severity [4–6]. Bilateral pulmonary infiltrates may be interstitial or alveolar with liters of pleural effusions observed during SNV infection [4–6, 8, 9].

Hantavirus antigen is found predominately in vast pulmonary capillary EC beds but is present in ECs within lymph nodes and throughout the body [8, 9, 80]. However, cytopathic effects are not evident following hantavirus infection of ECs *in vitro* or *in vivo* [9, 16, 82]. Histologically, the heart, kidneys, brain, and adrenals are grossly normal

with pulmonary alveoli filled with acellular proteinaceous fluid, yet the alveolar epithelium remains intact [4–6, 8, 9]. The most striking HPS findings are edematous lungs with up to 8 liters of pleural edema [5, 6, 8, 9]. Pulmonary edema fluid contains few leukocytes, is largely serous in nature, and is consistent with the nearly complete loss of an alveolar capillary fluid barrier [4–6, 9]. The lack of disrupted endothelium during HPS is similar to edematous pulmonary responses observed in patients with high altitude-induced pulmonary edema [40, 60, 110–112]. The rapid onset of edematous symptoms during hantavirus infection [6] further suggests the importance of targeting vessel stability in regulating highly lethal hantavirus disease.

3. Vascular and Lymphatic Endothelium: Control of Vascular Fluid Barrier Functions

The endothelium lines a series of discrete vessel types that conduct fluids to and from tissues, directs the transfer of nutrients, wastes and oxygen and coordinates tissue responses to changing conditions and pathogens [22, 24, 27, 54, 59, 113–119]. Vascular ECs serve mainly as a conduit in the lining of high pressure arteries but take on a variety of fluid and cellular barrier functions in low pressure veins and capillaries that innervate organs and tissues [54]. Lymphatic vessels have a primary role in draining fluid, proteins, and immune cells from tissues and returning these components to the venous circulation [42, 52–54, 114]. Depending on their location, lymphatic vessels serve discrete fluid barrier and regulatory functions, keeping pulmonary alveolar spaces dry and clearing fluid influx from the lungs [54, 61, 120]. These diverse EC settings require discrete EC functions to effect exchange within large capillary beds of the kidney, liver, and lung [27, 54].

The EC lining is responsible for controlling vessel damage through a complex mechanism of negative regulation, rapid response and proliferation [22, 24, 40, 53, 120, 121]. Unless activated, the endothelium normally prevents immune cells and platelets from adhering to its surface [22, 122]. Endothelial quiescence is maintained by several mediators, while vascular injury activates clotting factors, platelets, and ECs resulting in the recruitment of platelets to the endothelium [22]. ECs also have angiogenic roles migrating and proliferating to fill in endothelial cell gaps or to rebuild damaged vessels [29, 123]. EC migration and vessel remodeling requires changes in cell adherence within the endothelium, and carefully orchestrated receptor signaling responses are required to accomplish this without causing edema.

The endothelial fluid barrier is primarily derived from unique adherens junctions (AJs) composed of an EC-specific vascular-endothelial cadherin (VE-cadherin) [25, 30, 45, 96, 117, 119, 124]. EC barrier functions are increased by the presence of cell surface VE-cadherin and reduced by the dissociation and internalization of VE-cadherin [25, 30, 117]. Phosphorylated VE-cadherin is internalized by its interaction with intracellular actin complexes and this process is regulated by a variety of cellular receptors and intracellular signaling pathways [25, 124, 125]. VE-cadherin

phosphorylation is downregulated by an EC-specific phosphatase (VE-phosphatase) [124, 125] and several pathways that either directly or indirectly induce AJ assembly and EC integrity by returning VE-cadherin to an unphosphorylated resting state [25, 117, 125]. Chemokines, cytokines, and growth factors indirectly act on EC adherens junctions to increase vascular permeability and thus have the potential to contribute to pathogenic vascular leakage [27, 29, 96].

4. Unique Receptors Regulate EC Permeability

The endothelium contains many unique receptors that regulate AJ assembly and positively or negatively impact AJ stability and vascular integrity [33, 96, 126–129]. Vascular endothelial growth factor (VEGF) binds to EC-specific VEGFR2 receptors and activates a Src-Rac-Pak-VE-cadherin pathway resulting in AJ disassembly and vascular permeability [25, 30, 117]. Specialized ECs contain unique VEGFR1/2/3 that respond to novel forms of VEGF (VEGF A-E) and control AJ disassembly [61, 96, 130]. LECs uniquely express VEGFR3 on their surfaces and respond to VEGF-C/D but also coexpress VEGF-A responsive VEGFR2 receptors and are further regulated by the formation of VEGFR 2/3 heterodimers [39, 42, 53, 131].

VEGF was originally discovered as a potent vascular permeability factor that induces acute edema [29, 132]. VEGF reportedly acts within 0.5 mm of its release [133], and circulating soluble VEGFRs prevent VEGF from systemically permeabilizing vessels [39, 132]. VEGF is induced by hypoxia, and reduced oxygen levels at high altitudes cause high-altitude-induced pulmonary edema (HAPE) [35, 40, 113]. This results from activating the hypoxia-induced transcription factor-1 α (HIF-1 α), which senses oxygen levels and transcriptionally induces VEGF [59, 128, 134, 135]. VEGF further upregulates HIF-1 α , forming an autocrine loop, which amplifies hypoxia-mediated VEGF responses and causes HAPE [59, 113, 136, 137]. Although this response fosters increased gas exchange, in continued low-oxygen environments these cellular responses, instead cause pulmonary edema and in HAPE, respiratory distress [40, 110, 113, 128].

As part of the normal process of vascular repair and angiogenesis, ECs migrate in response to VEGF-A stimulation in the presence of extracellular matrix [41, 95, 138]. Permeabilizing VEGFR2 responses are normally controlled by specific cell surface integrins that modulate VEGFR2 complex formation, signaling and permeability responses [96, 97, 116, 139, 140]. Ectodomains of $\alpha_v\beta_3$ and VEGFR2 form complexes that direct EC migration, a process that requires AJ disassembly, yet need to limit VEGF-A-induced permeability [96, 139]. Knocking out β_3 integrins or antagonizing $\alpha_v\beta_3$ results in enhanced VEGF-A directed permeability of capillaries *in vivo* and *in vitro* [97, 141, 142]. $\alpha_v\beta_3$ antagonists are reported to promote the rapid recycling of internalized VEGFR2 to the cell surface, amplifying EC responses to VEGF [96, 97, 143].

β_3 integrin functions are further regulated by interactions with cell surface syndecan-1 and additional interactions of

neuropilin-1 (Nrp-1) with VEGFR2 [127, 142, 144–147]. Nrp-1 is a VEGF-A coreceptor that forms an ectodomain complex with VEGFR2 that regulates the permeabilizing effects of VEGF [127, 142, 144, 145], and Nrp-1 binding to VEGFR2 is further regulated by the binding of semaphorin3A (sema3A) [145–147]. Endothelial roundabout receptors, Robo1 and Robo4, also impact VEGFR2-directed permeability through discrete signaling pathways [36, 48, 148–150]. Slit-2 binding to Robo1 and Robo4, respectively, have positive or negative effects on VEGF-A directed EC permeability [151, 152]. However, Robo 1/4 are differentially expressed in discrete EC beds suggesting the localized permeability effects of slit-2 [148, 152]. These findings indicate that many EC responses control capillary leakage through interconnected mechanisms and suggest that altering any number of orchestrated EC barrier functions can result in edema.

5. Hantavirus-Endothelial Cell Interactions

5.1. Hantavirus Binding to Inactive $\alpha_v\beta_3$ Integrins Regulates EC Functions and Permeability. Pathogenic hantaviruses bind to inactive, basal conformations of $\alpha_v\beta_3$ integrin receptors on ECs, while nonpathogenic hantaviruses interact with discrete integrins [76, 77, 79]. Receptor binding directs viral entry, but at late times postinfection cell associated hantaviruses also negatively impact $\alpha_v\beta_3$ integrin functions [15–18, 20, 62]. Days after infection, cell-associated pathogenic hantaviruses block $\alpha_v\beta_3$ integrin directed EC migration and direct the binding of quiescent platelets to the EC surface [15, 62]. Similar to antagonizing or knocking out $\alpha_v\beta_3$ integrins [96, 97], pathogenic hantavirus infection of human ECs sensitizes monolayers to the permeabilizing effects of VEGF [16, 17]. SNV-, ANDV-, and HTNV-infected ECs, but not nonpathogenic PHV or TULV infected ECs, are hyperresponsive to the permeabilizing effects of VEGF [16], and VEGFR2 is hyperphosphorylated following pathogenic hantavirus infection [15, 17, 18]. Additionally, enhanced permeability of infected ECs only occurs days after infection when cell-associated hantaviruses coat the cell surface and inactivate $\alpha_v\beta_3$ integrins [15–17, 20, 73]. These findings, in the context of hypoxic HPS patients, suggest that hantavirus binding to inactive $\alpha_v\beta_3$ integrins contributes to capillary permeability in HPS. These results further suggest a mechanism for hantavirus-enhanced EC permeability that stems from disrupting normal $\alpha_v\beta_3$ -VEGFR2 interactions and enhanced VEGFR2-Src-VE-cadherin signaling responses that dissociate VE-cadherin from AJs [15–17, 20, 25, 96].

One paper suggests that ANDV-infected ECs transiently induce VEGF secretion, VE-cadherin degradation, and increased EC monolayer permeability [21]. However, several studies indicate that monolayers of hantavirus-infected ECs are not permeabilized by infection alone [16, 17, 82] and instead indicate that pathogenic hantavirus infected ECs are hyperpermeabilized by VEGF [16]. Collectively, these findings demonstrate that cell surface hantaviruses alter normal EC functions that control VEGF-directed vascular permeability [15–18, 62, 153].

5.2. Potential Role of LECs in Hantavirus Edema. Pulmonary lymphatic vessels are responsible for clearing fluid from alveoli and providing a semidry state that permits gas exchange [52, 54]. Failure of lymphatic vessels to clear fluids results in lymphedema and suggests an additional mechanism for hantavirus-infected LECs to contribute to acute pulmonary edema during HPS [42, 53, 54, 154]. Analysis of pathology samples from HPS patients indicates that hantavirus antigen is present in LECs of patient lymph nodes [8, 9, 80]. Although less is known about LECs, as described above, LECs express unique cell surface receptors and their integrity is regulated by both VEGF-A and VEGF-C [42, 53, 54, 61]. Interestingly, LEC VEGFR3 receptors respond to VEGF-C and are associated with reduced tissue edema [42, 61], while inhibiting VEGFR3 signaling results in lymphedema [42, 131]. Although a recent publication indicates that ANDV infects LECs and alters LEC barrier functions [155], the role of lymphatic vessels and LEC responses remains to be investigated in HPS patients.

5.3. Hantavirus-Endothelial Edemagenic Mechanisms. Prominent pulmonary and renal dysfunction are components of both HPS and HFRS diseases and likely stem from hantavirus infection of ECs, which line vast alveolar and renal capillary beds [4–6, 8, 9, 156, 157]. HPS patients are often young adults that arrive at hospitals in acute respiratory distress [4]. Acute pulmonary edema is a hallmark of HPS, with bilateral fluid infiltrates accumulating at up to a liter per hour resulting in pulmonary insufficiency and patient hypoxia during a critical phase of the disease [4, 6, 8, 9]. The cause of acute edema following hantavirus infection is likely to be multifactorial [6, 15–18, 64, 153, 155, 158] but revolves around the ability of the hantaviruses to infect ECs within alveolar capillary beds that normally regulate edema and gas exchange within the lung.

Clues to the mechanism of hantavirus-induced edema come from disparate findings on the role of hypoxia in acute pulmonary edema and the role of $\alpha_v\beta_3$ and VEGFR2 EC responses, which are uniquely altered by pathogenic hantaviruses [6, 15, 16, 20, 155]. Hypoxia is a prominent component of HPS patients and directs VEGF secretion from endothelial, epithelial, and immune cells [5, 6, 8, 9]. Consistent with the enhanced permeability of hantavirus-infected ECs in response to VEGF [16], HPS may be the result of hypoxia-induced VEGF that leads to acute pulmonary edema and may be exacerbated by reduced lymphatic vessel fluid clearance [155]. In fact, HPS patient VEGF levels were markedly elevated in pulmonary edema fluid and PBMCs in acute early phases of HPS [159]. Although a demonstrated role for hypoxia in hantavirus-induced permeability has yet to be conclusively defined, the ability of extracorporeal membrane oxygenation (ECMO) to reduce HPS patient mortality [4, 6] strongly suggests a role for hypoxia and VEGF in the acute pulmonary edema of HPS patients.

6. Animal HPS Model

Only ANDV infection of Syrian hamsters (*Mesocricetus auratus*) serves as a model of hantavirus pathogenesis that mimics

human HPS in onset symptoms and lethal acute respiratory disease [19, 160, 161]. Inoculation of Syrian hamsters with ANDV, but not SNV or other HPS causing hantaviruses, induces pathology approximating human disease. ANDV causes a fatal infection of Syrian hamsters with an LD₅₀ of 8 plaque-forming units. The disease is characterized by large pleural effusions, congested lungs, and interstitial pneumonitis in the absence of disrupted endothelium [19, 160, 161]. The onset of pulmonary edema coincides with a rapid increase in viremia on day 6, and large inclusion bodies and vacuoles in ultrastructural studies of infected pulmonary ECs [160, 161]. Viral antigen was localized to capillary ECs, alveolar macrophages, and splenic follicular marginal zones populated by dendritic cells. Interestingly, depletion of CD4 and CD8 T-cells had no effect on the onset, course, symptoms, or outcome of ANDV infection and indicates the absence of T-cell responses [19]. Consistent with the potential involvement of β_3 integrins and VEGF in this process, ANDV binds to conserved residues within PSI domains of both human and hamster β_3 integrins [20, 79]. Thus the mechanism of pathogenesis caused by ANDV is consistent with hypoxia-VEGF-directed acute pulmonary edema that occurs in the absence of T-cell-mediated pathology [19]. These findings differ from a report associating T-cell responses with HPS disease, although the same data support a lack of T-cell involvement, since half of HPS patients had no elevated T-cell responses regardless of disease severity [64]. Observed T-cell responses may instead correlate with viral clearance [63, 162]. The mechanism of pathogenesis may be further elucidated by studies in Syrian hamsters and thus provides a model of ANDV pathogenesis that permits the evaluation of therapeutics that target barrier functions of the endothelium.

7. Targeted Therapeutic Approaches for Stabilizing the Endothelium

Currently, there are no effective therapeutics for hantavirus infections or disease. Antiviral effects of interferon or the nucleoside analog ribavirin are only effective prophylactically or at very early times postinfection [14, 163]. They appear to target early viral replication but neither is effective 1–2 weeks postinfection after the onset of HPS symptoms [4–6, 163]. An alternative approach against viruses with a long disease onset may be to therapeutically target the acute pathologic response instead of viral replication. Since hantaviruses infect and alter fluid barrier functions of the endothelium, targeting EC responses that transiently stabilize the vasculature has the potential to reduce the severity and mortality of HPS [50, 129, 164]. This approach also has the advantage of being implemented at the onset of symptoms where antiviral approaches appear to be ineffective [163].

Intracellular signaling pathways coordinately regulate the adherence of ECs to the extracellular matrix, anchor receptors to cytoskeletal elements, and induce growth factor directed migration, proliferation and permeability responses [18, 35, 41, 43, 50, 96, 116, 165, 166]. The complexity of VEGF induced permeability is further demonstrated by the

reported ability of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling responses, to block VEGF-induced microvascular permeability [167–171]. This multifactorial coordination indicates why so many factors are capable of permeabilizing or stabilizing the endothelium and rationalizes their potential roles in pathogen-induced capillary leakage.

Antibody to VEGFR2 reportedly suppresses VEGF-induced pulmonary edema and suggests the potential of therapeutically antagonizing VEGFR2-Src-VE-cadherin signaling pathways as a means of reducing acute pulmonary edema during HPS [18, 25, 39, 50, 172–176]. Several well-studied VEGFR2 and Src inhibitors are in human clinical trials or are used therapeutically to treat human cancers and have the potential to reduce the severity of viral permeability-based diseases [18, 42, 50, 173, 174, 177–179]. *In vitro*, angiopoietin-1 (Ang-1), sphingosine-1-phosphate (S1P), pazopanib, and dasatinib inhibited EC permeability directed by pathogenic hantaviruses [16, 18]. Ang-1 is an EC-specific growth factor that transdominantly blocks VEGFR2-directed permeability *in vitro* and *in vivo* by binding to Tie-2 receptors [180–183]. S1P is a platelet derived lipid mediator, which enhances vascular barrier functions by binding to Edg-1 receptors on the endothelium [47, 172, 173, 179, 184], while pazopanib and dasatinib are drugs that inhibit VEGFR2-Src signaling [174, 185]. Pazopanib, dasatinib, and the S1P analog FTY720 are already in clinical trials or used clinically for other purposes [34, 186]. Targeting EC responses provides a potential means of stabilizing HPS patient vessels and reducing edema. The use of S1P receptor agonists has also been shown to regulate the pathogenesis of influenza virus infection by acting on ECs and reducing immune cell recruitment and entry into the lung [172]. These findings suggest the targeting of EC functions as a means of increasing capillary barrier functions and regulating immune responses that contribute to viral pathogenesis.

The regulation of additional EC receptors that stabilize interendothelial cell AJs and fluid barrier functions of the endothelium may be considered as therapeutic targets. The Robo4 receptor has been shown to inhibit VEGFR2 responses, stabilize vessels and block vascular permeability [48, 148, 152]. This new potential target is highly expressed by lung microvascular ECs and is currently being evaluated as a therapeutic for a variety of vascular disorders [149, 152]. However, Robo4 directed stability of interendothelial cell junctions may also be applicable to reducing HPS severity.

Several additional EC receptors that bind to VEGFR2 ectodomains positively or negatively regulate $\alpha_v\beta_3$ -VEGFR2 functions and may provide additional therapeutic targets for regulating vascular permeability. Potential responses which need to be investigated as therapeutic targets include: NRP1, Syndecan1 (sdc1), and the insulin-like growth factor1 receptor (IGF1R), which are recruited to $\alpha_v\beta_3$ ectodomain complexes [49, 141, 142, 144, 175, 187, 188]: Surfen, a heparan sulfate containing protein that reportedly blocks EC permeability [189], and Fibulin-5, a matrix protein that reportedly promotes EC adherence by binding $\alpha_v\beta_3$ and is associated with emphysema [190–192]. However, inhibiting β_3 receptors that are present on both platelets and ECs may

exacerbate permeability and thus the choice of therapeutic targets is likely to be critical to increasing fluid barrier functions of the endothelium. Targeting the VEGFR2 axis that regulates EC permeability may be a central mechanism for stabilizing the endothelium and reducing the severity of HPS [127, 145, 175, 193].

These findings suggest a plethora of targets that may regulate virally induced vascular permeability and which are already clinically approved for other indications. Moreover, targeting these responses may be broadly applicable to reducing the severity of HFRS and a wide range of viral infections that impact the endothelium and cause edematous diseases.

8. Future Directions and Conclusions

The endothelium plays a fundamental role in vascular disease, and stabilizing the vasculature needs to be evaluated as a means for reducing the severity and mortality of viral vascular diseases. This is especially important for viral infections that cause disease 1–2 weeks after infection, at time points when antiviral approaches are no longer viable. The ability of hantaviruses to infect LECs and alter normal fluid clearance from tissues needs to be investigated and provides a unique target and mechanism for reducing edema that has yet to be considered in HPS disease. The ability of the endothelium to regulate platelet functions, complement activation, and immune responses should also be considered as central targets for reducing the severity of viral hemorrhagic and edematous diseases.

References

- [1] M. Kanerva, J. Mustonen, and A. Vaheri, "Pathogenesis of puumala and other hantavirus infections," *Reviews in Medical Virology*, vol. 8, no. 2, pp. 67–86, 1998.
- [2] P. Heyman, A. Vaheri, A. Lundkvist, and T. Avsic-Zupanc, "Hantavirus infections in Europe: from virus carriers to a major public-health problem," *Expert Review of Anti-Infective Therapy*, vol. 7, no. 2, pp. 205–217, 2009.
- [3] H. W. Lee, R. W. Lee, and K. M. Johnson, "Isolation of the etiologic agent of Korean hemorrhagic fever," *Journal of Infectious Diseases*, vol. 137, no. 3, pp. 298–308, 1978.
- [4] B. Chang, M. Crowley, M. Campen, and F. Koster, "Hantavirus cardiopulmonary syndrome," *Seminars in Respiratory and Critical Care Medicine*, vol. 28, no. 2, pp. 193–200, 2007.
- [5] J. S. Duchin, F. T. Koster, C. J. Peters et al., "Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease," *The New England Journal of Medicine*, vol. 330, no. 14, pp. 949–955, 1994.
- [6] F. Koster and E. Mackow, "Pathogenesis of the hantavirus pulmonary syndrome," *Future Virology*, vol. 7, no. 1, pp. 41–51, 2012.
- [7] S. T. Nichol, C. F. Spiropoulou, S. Morzunov et al., "Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness," *Science*, vol. 262, no. 5135, pp. 914–917, 1993.
- [8] K. B. Nolte, R. M. Feddersen, K. Foucar et al., "Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent," *Human Pathology*, vol. 26, no. 1, pp. 110–120, 1995.
- [9] S. R. Zaki, P. W. Greer, L. M. Coffield et al., "Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease," *American Journal of Pathology*, vol. 146, no. 3, pp. 552–579, 1995.
- [10] J. Lähdevirta, E. Enger, O. H. Hunderi, T. Traavik, and H. W. Lee, "Hantaan virus is related to hemorrhagic fever with renal syndrome in Norway," *The Lancet*, vol. 2, no. 8298, p. 606, 1982.
- [11] H. W. Lee, "Hemorrhagic fever with renal syndrome (HFRS). History, Hantaan virus and epidemiological features," *Scandinavian Journal of Infectious Diseases*, vol. 14, no. 36, pp. 82–85, 1982.
- [12] R. Yanagihara and D. J. Silverman, "Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses," *Archives of Virology*, vol. 111, no. 3–4, pp. 281–286, 1990.
- [13] B. Hjelle and F. Torres-Pérez, "Hantaviruses in the Americas and their role as emerging pathogens," *Viruses*, vol. 2, no. 12, pp. 2559–2586, 2010.
- [14] C. Schmaljohn, "Bunyaviridae and their replication," in *Fields Virology*, D. M. Knipe and P. M. Howley, Eds., vol. 1, pp. 1581–1602, Lippincott-Raven, Philadelphia, Pa, USA, 2001.
- [15] I. N. Gavrilovskaya, E. E. Gorbunova, and E. R. Mackow, "Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells," *Journal of Virology*, vol. 84, no. 9, pp. 4832–4839, 2010.
- [16] I. N. Gavrilovskaya, E. E. Gorbunova, N. A. Mackow, and E. R. Mackow, "Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability," *Journal of Virology*, vol. 82, no. 12, pp. 5797–5806, 2008.
- [17] E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow, "Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cell," *Journal of Virology*, vol. 84, no. 14, pp. 7405–7411, 2010.
- [18] E. E. Gorbunova, I. N. Gavrilovskaya, T. Pepini, and E. R. Mackow, "VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability," *Journal of Virology*, vol. 85, no. 5, pp. 2296–2303, 2011.
- [19] C. D. Hammerbeck and J. W. Hooper, "T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome," *Journal of Virology*, vol. 85, no. 19, pp. 9929–9944, 2011.
- [20] T. Raymond, E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow, "Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent $\alpha v \beta 3$ integrin conformers," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 4, pp. 1163–1168, 2005.
- [21] P. Shrivastava-Ranjan, P. E. Rollin, and C. F. Spiropoulou, "Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin," *Journal of Virology*, vol. 84, no. 21, pp. 11227–11234, 2010.
- [22] W. C. Aird, "Endothelium as an organ system," *Critical Care Medicine*, vol. 32, no. 5, pp. S271–279, 2004.
- [23] S. M. Baumgartner-Parzer and W. K. Waldhäusl, "The endothelium as a metabolic and endocrine organ: its relation with insulin resistance," *Experimental and Clinical Endocrinology and Diabetes*, vol. 109, no. 2, pp. S166–S179, 2001.

- [24] G. Valbuena and D. H. Walker, "The endothelium as a target for infections," *Annual Review of Pathology*, vol. 1, pp. 171–198, 2006.
- [25] J. Gavard, "Breaking the VE-cadherin bonds," *FEBS Letters*, vol. 583, no. 1, pp. 1–6, 2009.
- [26] D. O. Bates and S. J. Harper, "Regulation of vascular permeability by vascular endothelial growth factors," *Vascular Pharmacology*, vol. 39, no. 4–5, pp. 225–237, 2002.
- [27] D. B. Cines, E. S. Pollak, C. A. Buck et al., "Endothelial cells in physiology and in the pathophysiology of vascular disorders," *Blood*, vol. 91, no. 10, pp. 3527–3561, 1998.
- [28] M. Corada, M. Mariotti, G. Thurston et al., "Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 17, pp. 9815–9820, 1999.
- [29] H. F. Dvorak, L. F. Brown, M. Detmar, and A. M. Dvorak, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis," *American Journal of Pathology*, vol. 146, no. 5, pp. 1029–1039, 1995.
- [30] J. Gavard and J. S. Gutkind, "VEGF Controls endothelial-cell permeability promoting β -arrestin-dependent Endocytosis VE-cadherin," *Nature Cell Biology*, vol. 8, no. 11, pp. 1223–1234, 2006.
- [31] S. Hippenstiel, M. Krüll, A. Ikemann, W. Risau, M. Clauss, and N. Suttorp, "VEGF induces hyperpermeability by a direct action on endothelial cells," *American Journal of Physiology*, vol. 274, no. 5, pp. L678–L684, 1998.
- [32] P. L. Hordijk, "Endothelial signaling in leukocyte transmigration," *Cell Biochemistry and Biophysics*, vol. 38, no. 3, pp. 305–322, 2003.
- [33] M. G. Lampugnani, F. Orsenigo, M. C. Gagliani, C. Tacchetti, and E. Dejana, "Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments," *Journal of Cell Biology*, vol. 174, no. 4, pp. 593–604, 2006.
- [34] B. J. McVerry and J. G. N. Garcia, "Endothelial cell barrier regulation by sphingosine 1-phosphate," *Journal of Cellular Biochemistry*, vol. 92, no. 6, pp. 1075–1085, 2004.
- [35] D. Mukhopadhyay, L. Tsiokas, X. M. Zhou, D. Foster, J. S. Brugge, and V. P. Sukhatme, "Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation," *Nature*, vol. 375, no. 6532, pp. 577–581, 1995.
- [36] K. W. Park, C. M. Morrison, L. K. Sorensen et al., "Robo4 is a vascular-specific receptor that inhibits endothelial migration," *Developmental Biology*, vol. 261, no. 1, pp. 251–267, 2003.
- [37] V. W. M. van Hinsbergh and G. P. van Nieuw Amerongen, "Endothelial hyperpermeability in vascular leakage," *Vascular Pharmacology*, vol. 39, no. 4–5, pp. 171–172, 2002.
- [38] Y. Shimizu, W. Newman, Y. Tanaka, and S. Shaw, "Lymphocyte interactions with endothelial cells," *Immunology Today*, vol. 13, no. 3, pp. 106–112, 1992.
- [39] E. C. Breen, "VEGF in biological control," *Journal of Cellular Biochemistry*, vol. 102, no. 6, pp. 1358–1367, 2007.
- [40] M. M. Berger, C. Hesse, C. Dehnert et al., "Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema," *American Journal of Respiratory and Critical Care Medicine*, vol. 172, no. 6, pp. 763–767, 2005.
- [41] B. S. Coller and S. J. Shattil, "The GPIIb/IIIa (integrin α IIb β 3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend," *Blood*, vol. 112, no. 8, pp. 3011–3025, 2008.
- [42] F. Bahram and L. Claesson-Welsh, "VEGF-mediated signal transduction in lymphatic endothelial cells," *Pathophysiology*, vol. 17, no. 4, pp. 253–261, 2010.
- [43] E. Brakenhielm, "Substrate matters: reciprocally stimulatory integrin and VEGF signaling in endothelial cells," *Circulation Research*, vol. 101, no. 6, pp. 536–538, 2007.
- [44] D. S. Gélinas, P. N. Bernatchez, S. Rollin, N. G. Bazan, and M. G. Sirois, "Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways," *British Journal of Pharmacology*, vol. 137, no. 7, pp. 1021–1030, 2002.
- [45] M. G. Lampugnani and E. Dejana, "The control of endothelial cell functions by adherens junctions," *Novartis Foundation Symposium*, vol. 283, pp. 238–241, 2007.
- [46] H. Kobayashi and P. C. Lin, "Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases," *Frontiers in Bioscience*, vol. 10, pp. 666–674, 2005.
- [47] Y. Takuwa, N. Takuwa, and N. Sugimoto, "The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities," *Journal of Biochemistry*, vol. 131, no. 6, pp. 767–771, 2002.
- [48] L. M. Acevedo, S. M. Weis, and D. A. Cheresh, "Robo4 counteracts VEGF signaling," *Nature Medicine*, vol. 14, no. 4, pp. 372–373, 2008.
- [49] D. M. Beauvais, B. J. Ell, A. R. McWhorter, and A. C. Rapraeger, "Syndecan-1 regulates α v β 3 and α v β 5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor," *Journal of Experimental Medicine*, vol. 206, no. 3, pp. 691–705, 2009.
- [50] J. Gavard, V. Patel, and J. S. Gutkind, "Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia," *Developmental Cell*, vol. 14, no. 1, pp. 25–36, 2008.
- [51] M. G. Lampugnani and E. Dejana, "Adherens junctions in endothelial cells regulate vessel maintenance and angiogenesis," *Thrombosis Research*, vol. 120, no. 2, supplement, pp. S1–S6, 2007.
- [52] P. Baluk, J. Fuxe, H. Hashizume et al., "Functionally specialized junctions between endothelial cells of lymphatic vessels," *Journal of Experimental Medicine*, vol. 204, no. 10, pp. 2349–2362, 2007.
- [53] P. Saharinen, T. Tammela, M. J. Karkkainen, and K. Alitalo, "Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation," *Trends in Immunology*, vol. 25, no. 7, pp. 387–395, 2004.
- [54] D. E. Schraufnagel, "Lung lymphatic anatomy and correlates," *Pathophysiology*, vol. 17, no. 4, pp. 337–343, 2010.
- [55] S. Esser, K. Wolburg, H. Wolburg, G. Breier, T. Kurzchalia, and W. Risau, "Vascular endothelial growth factor induces endothelial fenestrations in vitro," *Journal of Cell Biology*, vol. 140, no. 4, pp. 947–959, 1998.
- [56] R. J. Kaner, J. V. Ladetto, R. Singh, N. Fukuda, M. A. Matthay, and R. G. Crystal, "Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema," *American Journal of Respiratory Cell and Molecular Biology*, vol. 22, no. 6, pp. 657–664, 2000.
- [57] G. M. Mutlu and J. I. Sznajder, "Mechanisms of pulmonary edema clearance," *American Journal of Physiology*, vol. 289, no. 5, pp. L685–L695, 2005.
- [58] D. E. Schraufnagel, N. P. Agaram, A. Faruqui et al., "Pulmonary lymphatics and edema accumulation after brief lung injury," *American Journal of Physiology*, vol. 284, no. 5, pp. L891–L897, 2003.

- [59] M. Dehler, E. Zessin, P. Bärtsch, and H. Mairbäurl, "Hypoxia causes permeability oedema in the constant-pressure perfused rat lung," *European Respiratory Journal*, vol. 27, no. 3, pp. 600–606, 2006.
- [60] N. F. Voelkel, "High-altitude pulmonary edema," *The New England Journal of Medicine*, vol. 346, no. 21, pp. 1606–1607, 2002.
- [61] J. W. Breslin, N. Gaudreault, K. D. Watson, R. Reynoso, S. Y. Yuan, and M. H. Wu, "Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism," *American Journal of Physiology*, vol. 293, no. 1, pp. H709–H718, 2007.
- [62] I. N. Gavrilovskaya, T. Peresleni, E. Geimonen, and E. R. Mackow, "Pathogenic hantaviruses selectively inhibit $\beta 3$ integrin directed endothelial cell migration," *Archives of Virology*, vol. 147, no. 10, pp. 1913–1931, 2002.
- [63] T. Lindgren, C. Ahlm, N. Mohamed, M. Evander, H.-G. Ljunggren, and N. K. Björkström, "Longitudinal analysis of the human T cell response during acute hantavirus infection," *Journal of Virology*, vol. 85, no. 19, pp. 10252–10260, 2011.
- [64] E. D. Kilpatrick, M. Terajima, F. T. Koster, M. D. Catalina, J. Cruz, and F. A. Ennis, "Role of specific CD8⁺ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome," *Journal of Immunology*, vol. 172, no. 5, pp. 3297–3304, 2004.
- [65] A. J. Battisti, Y. K. Chu, P. R. Chipman, B. Kaufmann, C. B. Jonsson, and M. G. Rossmann, "Structural studies of Hantaan virus," *Journal of Virology*, vol. 85, no. 2, pp. 835–841, 2011.
- [66] C. B. Jonsson, L. T. M. Figueiredo, and O. Vapalahti, "A global perspective on hantavirus ecology, epidemiology, and disease," *Clinical Microbiology Reviews*, vol. 23, no. 2, pp. 412–441, 2010.
- [67] A. Plyusnin, O. Vapalahti, and A. Vaheri, "Hantaviruses: genome structure, expression and evolution," *Journal of General Virology*, vol. 77, no. 11, pp. 2677–2687, 1996.
- [68] C. Schmaljohn and B. Hjelle, "Hantaviruses: a global disease problem," *Emerging Infectious Diseases*, vol. 3, no. 2, pp. 95–104, 1997.
- [69] A. K. McElroy, J. M. Smith, J. W. Hooper, and C. S. Schmaljohn, "Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters," *Virology*, vol. 326, no. 1, pp. 130–139, 2004.
- [70] C. B. Jonsson and C. S. Schmaljohn, "Replication of hantaviruses," *Current Topics in Microbiology and Immunology*, vol. 256, pp. 15–32, 2000.
- [71] A. Alfadhli, Z. Love, B. Arvidson, J. Seeds, J. Willey, and E. Barklis, "Hantavirus nucleocapsid protein oligomerization," *Journal of Virology*, vol. 75, no. 4, pp. 2019–2023, 2001.
- [72] M. N. Pensiero and J. Hay, "The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently," *Journal of Virology*, vol. 66, no. 4, pp. 1907–1914, 1992.
- [73] C. S. Goldsmith, L. H. Elliott, C. J. Peters, and S. R. Zaki, "Ultrastructural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome," *Archives of Virology*, vol. 140, no. 12, pp. 2107–2122, 1995.
- [74] C. S. Schmaljohn, A. L. Schmaljohn, and J. M. Dalrymple, "Hantaan virus M RNA: coding strategy, nucleotide sequence, and gene order," *Virology*, vol. 157, no. 1, pp. 31–39, 1987.
- [75] M. N. Pensiero, G. B. Jennings, C. S. Schmaljohn, and J. Hay, "Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant," *Journal of Virology*, vol. 62, no. 3, pp. 696–702, 1988.
- [76] I. N. Gavrilovskaya, E. J. Brown, M. H. Ginsberg, and E. R. Mackow, "Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by $\beta 3$ integrins," *Journal of Virology*, vol. 73, no. 5, pp. 3951–3959, 1999.
- [77] I. N. Gavrilovskaya, M. Shepley, R. Shaw, M. H. Ginsberg, and E. R. Mackow, " $\beta 3$ integrins mediate the cellular entry of hantaviruses that cause respiratory failure," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 12, pp. 7074–7079, 1998.
- [78] E. R. Mackow and I. N. Gavrilovskaya, "Cellular receptors and hantavirus pathogenesis," *Current Topics in Microbiology and Immunology*, vol. 256, pp. 91–115, 2000.
- [79] V. S. Matthys, E. E. Gorbunova, I. N. Gavrilovskaya, and E. R. Mackow, "Andes virus recognition of human and syrian hamster $\beta 3$ integrins is determined by an L33P substitution in the PSI domain," *Journal of Virology*, vol. 84, no. 1, pp. 352–360, 2010.
- [80] T. M. Cosgriff and R. M. Lewis, "Mechanisms of disease in hemorrhagic fever with renal syndrome," *Kidney International*, vol. 40, no. 35, pp. S72–S79, 1991.
- [81] M. N. Pensiero, J. B. Sharefkin, C. W. Dieffenbach, and J. Hay, "Hantaan virus infection of human endothelial cells," *Journal of Virology*, vol. 66, no. 10, pp. 5929–5936, 1992.
- [82] J. B. Sundstrom, L. K. McMullan, C. F. Spiropoulou et al., "Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells," *Journal of Virology*, vol. 75, no. 13, pp. 6070–6085, 2001.
- [83] L. H. Elliott, T. G. Ksiazek, P. E. Rollin et al., "Isolation of the causative agent of hantavirus pulmonary syndrome," *American Journal of Tropical Medicine and Hygiene*, vol. 51, no. 1, pp. 102–108, 1994.
- [84] A. L. Schmaljohn, D. Li, D. L. Negley et al., "Isolation and initial characterization of a newfound hantavirus from California," *Virology*, vol. 206, no. 2, pp. 963–972, 1995.
- [85] A. Plyusnin, O. Vapalahti, H. Lankinen et al., "Tula virus: a newly detected hantavirus carried by European common voles," *Journal of Virology*, vol. 68, no. 12, pp. 7833–7839, 1994.
- [86] O. Vapalahti, A. Lundkvist, S. K. J. Kukkonen et al., "Isolation and characterization of Tula virus, a distinct serotype in the genus Hantavirus, family Bunyaviridae," *Journal of General Virology*, vol. 77, no. 12, pp. 3063–3067, 1996.
- [87] P. W. Lee, H. L. Amyx, and R. Yanagihara, "Partial characterization of Prospect Hill virus isolated from voles in the United States," *Journal of Infectious Diseases*, vol. 152, no. 4, pp. 826–829, 1985.
- [88] V. Matthys, E. E. Gorbunova, I. N. Gavrilovskaya, T. Pepini, and E. R. Mackow, "The C-terminal 42 residues of the tula virus Gn protein regulate interferon induction," *Journal of Virology*, vol. 85, no. 10, pp. 4752–4760, 2011.
- [89] E. Geimonen, S. Neff, T. Raymond, S. S. Kocer, I. N. Gavrilovskaya, and E. R. Mackow, "Pathogenic and non-pathogenic hantaviruses differentially regulate endothelial cell responses," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 21, pp. 13837–13842, 2002.
- [90] P. J. Alff, I. N. Gavrilovskaya, E. Gorbunova et al., "The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I- and TBK-1-directed interferon responses," *Journal of Virology*, vol. 80, no. 24, p. 12430, 2006.

- [91] P. J. Alff, N. Sen, E. Gorbunova, I. N. Gavrillovskaia, and E. R. Mackow, "The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation," *Journal of Virology*, vol. 82, no. 18, pp. 9115–9122, 2008.
- [92] B. H. Luo, J. Karanickolas, L. D. Harmacek, D. Baker, and T. A. Springer, "Rationally designed integrin $\beta 3$ mutants stabilized in the high affinity conformation," *Journal of Biological Chemistry*, vol. 284, no. 6, pp. 3917–3924, 2009.
- [93] B. H. Luo, J. Takagi, and T. A. Springer, "Locking the $\beta 3$ integrin I-like domain into high and low affinity conformations with disulfides," *Journal of Biological Chemistry*, vol. 279, no. 11, pp. 10215–10221, 2004.
- [94] J. Zhu, B. H. Luo, T. Xiao, C. Zhang, N. Nishida, and T. A. Springer, "Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces," *Molecular Cell*, vol. 32, no. 6, pp. 849–861, 2008.
- [95] R. O. Hynes, "Structural biology: changing partners," *Science*, vol. 300, no. 5620, pp. 755–756, 2003.
- [96] S. D. Robinson, L. E. Reynolds, L. Wyder, D. J. Hicklin, and K. M. Hodivala-Dilke, " $\beta 3$ -integrin regulates vascular endothelial growth factor-A-dependent permeability," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, no. 11, pp. 2108–2114, 2004.
- [97] S. M. Weis and D. A. Cheresh, "alphav Integrins in Angiogenesis and Cancer," *Cold Spring Harbor Perspectives in Medicine*, vol. 1, no. 1, Article ID a006478.
- [98] K. M. Hodivala-Dilke, K. P. McHugh, D. A. Tsakiris et al., " $\beta 3$ -integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival," *Journal of Clinical Investigation*, vol. 103, no. 2, pp. 229–238, 1999.
- [99] R. O. Hynes, B. L. Bader, and K. Hodivala-Dilke, "Integrins in vascular development," *Brazilian Journal of Medical and Biological Research*, vol. 32, no. 5, pp. 501–510, 1999.
- [100] D. L. French and B. S. Collier, "Hematologically important mutations: glanzmann thrombasthenia," *Blood Cells, Molecules and Diseases*, vol. 23, no. 1, pp. 39–51, 1997.
- [101] N. López, P. Padula, C. Rossi, M. E. Lázaro, and M. T. Franze-Fernández, "Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina," *Virology*, vol. 220, no. 1, pp. 223–226, 1996.
- [102] D. Enria, P. Padula, E. L. Segura et al., "Hantavirus pulmonary syndrome in Argentina possibility of person to person transmission," *Medicina*, vol. 56, no. 6, pp. 709–711, 1996.
- [103] P. J. Padula, A. Edelstein, S. D. L. Miguel, N. M. López, C. M. Rossi, and R. D. Rabinovich, "Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus," *Virology*, vol. 241, no. 2, pp. 323–330, 1998.
- [104] P. J. Padula, A. J. Sanchez, A. Edelstein, and S. T. Nichol, "Complete nucleotide sequence of the M RNA segment of Andes virus and analysis of the variability of the termini of the virus S, M and L RNA segments," *Journal of General Virology*, vol. 83, no. 9, pp. 2117–2122, 2002.
- [105] J. W. Song, L. J. Baek, D. C. Gajdusek et al., "Isolation of pathogenic hantavirus from white-footed mouse (*Peromyscus leucopus*)," *The Lancet*, vol. 344, no. 8937, p. 1637, 1994.
- [106] F. Koster, K. Foucar, B. Hjelle et al., "Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review," *American Journal of Clinical Pathology*, vol. 116, no. 5, pp. 665–672, 2001.
- [107] S. Levis, J. E. Rowe, S. Morzunov, D. A. Enria, and S. St Jeor, "New hantaviruses causing hantavirus pulmonary syndrome in central Argentina," *The Lancet*, vol. 349, no. 9057, pp. 998–999, 1997.
- [108] E. A. Bustamante, H. Levy, and S. Q. Simpson, "Pleural fluid characteristics in hantavirus pulmonary syndrome," *Chest*, vol. 112, no. 4, pp. 1133–1136, 1997.
- [109] G. W. Hallin, S. Q. Simpson, R. E. Crowell et al., "Cardiopulmonary manifestations of hantavirus pulmonary syndrome," *Critical Care Medicine*, vol. 24, no. 2, pp. 252–258, 1996.
- [110] M. Hanaoka, Y. Droma, A. Naramoto, T. Honda, T. Kobayashi, and K. Kubo, "Vascular endothelial growth factor in patients with high-altitude pulmonary edema," *Journal of Applied Physiology*, vol. 94, no. 5, pp. 1836–1840, 2003.
- [111] R. J. Kaner and R. G. Crystal, "Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung," *Molecular Medicine*, vol. 7, no. 4, pp. 240–246, 2001.
- [112] R. J. Kaner and R. G. Crystal, "Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak?" *High Altitude Medicine and Biology*, vol. 5, no. 4, pp. 399–409, 2004.
- [113] H. Christou, A. Yoshida, V. Arthur, T. Morita, and S. Kourembanas, "Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension," *American Journal of Respiratory Cell and Molecular Biology*, vol. 18, no. 6, pp. 768–776, 1998.
- [114] J. W. Breslin and K. M. Kurtz, "Lymphatic endothelial cells adapt their barrier function in response to changes in shear stress," *Lymphatic Research and Biology*, vol. 7, no. 4, pp. 229–237, 2009.
- [115] A. Basu and U. C. Chaturvedi, "Vascular endothelium: the battlefield of dengue viruses," *FEMS Immunology and Medical Microbiology*, vol. 53, no. 3, pp. 287–299, 2008.
- [116] T. V. Byzova, C. K. Goldman, N. Pampori et al., "A mechanism for modulation of cellular responses to VEGF: activation of the integrins," *Molecular Cell*, vol. 6, no. 4, pp. 851–860, 2000.
- [117] E. Dejana, F. Orsenigo, and M. G. Lampugnani, "The role of adherens junctions and VE-cadherin in the control of vascular permeability," *Journal of Cell Science*, vol. 121, no. 13, pp. 2115–2122, 2008.
- [118] N. R. London, K. J. Whitehead, and D. Y. Li, "Endogenous endothelial cell signaling systems maintain vascular stability," *Angiogenesis*, vol. 12, no. 2, pp. 149–158, 2009.
- [119] Y. Wallez, I. Vilgrain, and P. Huber, "Angiogenesis: the VE-cadherin switch," *Trends in Cardiovascular Medicine*, vol. 16, no. 2, pp. 55–59, 2006.
- [120] P. Baluk, T. Tammela, E. Ator et al., "Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation," *Journal of Clinical Investigation*, vol. 115, no. 2, pp. 247–257, 2005.
- [121] A. K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh, "VEGF receptor signalling—in control of vascular function," *Nature Reviews Molecular Cell Biology*, vol. 7, no. 5, pp. 359–371, 2006.
- [122] R. M. Nalbandian and R. L. Henry, "Platelet endothelial cell interactions. Metabolic maps of structures and actions of prostaglandins, prostacyclin, thromboxane and cyclic AMP," *Seminars in Thrombosis and Hemostasis*, vol. 5, no. 2, pp. 87–111, 1978.
- [123] D. Gomez and N. C. Reich, "Stimulation of primary human endothelial cell proliferation by IFN1," *Journal of Immunology*, vol. 170, no. 11, pp. 5373–5381, 2003.

- [124] R. Nawroth, G. Poell, A. Ranft et al., "VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts," *EMBO Journal*, vol. 21, no. 18, pp. 4885–4895, 2002.
- [125] A. Broermann, M. Winderlich, H. Block et al., "Dissociation of VE-PTP from ve-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo," *Journal of Experimental Medicine*, vol. 208, no. 12, pp. 2393–2401, 2011.
- [126] F. Galvagni, S. Pennacchini, A. Salameh et al., "Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity," *Circulation Research*, vol. 106, no. 12, pp. 1839–1848, 2010.
- [127] S. Soker, H. Q. Miao, M. Nomi, S. Takashima, and M. Klagsbrun, "VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding," *Journal of Cellular Biochemistry*, vol. 85, no. 2, pp. 357–368, 2002.
- [128] K. R. Stenmark, K. A. Fagan, and M. G. Frid, "Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms," *Circulation Research*, vol. 99, no. 7, pp. 675–691, 2006.
- [129] J. G. N. Garcia, F. Liu, A. D. Verin et al., "Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement," *Journal of Clinical Investigation*, vol. 108, no. 5, pp. 689–701, 2001.
- [130] G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, "Vascular endothelial growth factor (VEGF) and its receptors," *FASEB Journal*, vol. 13, no. 1, pp. 9–22, 1999.
- [131] I. Nilsson, F. Bahram, X. Li et al., "VEGF receptor 2/3 heterodimers detected in situ by proximity ligation on angiogenic sprouts," *EMBO Journal*, vol. 29, no. 8, pp. 1377–1388, 2010.
- [132] H. F. Dvorak, "Discovery of vascular permeability factor (VPF)," *Experimental Cell Research*, vol. 312, no. 5, pp. 522–526, 2006.
- [133] H. F. Dvorak, T. M. Sioussat, L. F. Brown et al., "Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels," *Journal of Experimental Medicine*, vol. 174, no. 5, pp. 1275–1278, 1991.
- [134] K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Cross, "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition," *Cellular Signalling*, vol. 19, no. 10, pp. 2003–2012, 2007.
- [135] N. Tang, L. Wang, J. Esko et al., "Loss of HIF-1 α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis," *Cancer Cell*, vol. 6, no. 5, pp. 485–495, 2004.
- [136] I. Pham, T. Uchida, C. Planes et al., "Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo," *American Journal of Physiology*, vol. 283, no. 5, pp. L1133–L1142, 2002.
- [137] I. N. Sidel'nikov and N. I. Anisimova, "The mechanisms of the development of tissue hypoxia and the criteria for its assessment in patients with hemorrhagic fever with renal syndrome," *Terapevticheskii Arkhiv*, vol. 63, no. 11, pp. 68–70, 1991.
- [138] H. Hutchings, N. Ortega, and J. Plouët, "Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation," *The FASEB Journal*, vol. 17, no. 11, pp. 1520–1522, 2003.
- [139] E. Borges, Y. Jan, and E. Ruoslahti, "Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β 3 integrin through its extracellular domain," *Journal of Biological Chemistry*, vol. 275, no. 51, pp. 39867–39873, 2000.
- [140] L. E. Reynolds, L. Wyder, J. C. Lively et al., "Enhanced pathological angiogenesis in mice lacking β 3 integrin or β 3 and β 5 integrins," *Nature Medicine*, vol. 8, no. 1, pp. 27–34, 2002.
- [141] S. Soker, S. Takashima, H. Q. Miao, G. Neufeld, and M. Klagsbrun, "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor," *Cell*, vol. 92, no. 6, pp. 735–745, 1998.
- [142] L. Wang, H. Zeng, P. Wang, S. Soker, and D. Mukhopadhyay, "Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration," *The Journal of Biological Chemistry*, vol. 278, no. 49, pp. 48848–48860, 2003.
- [143] R. O. Hynes and K. M. Hodivala-Dilke, "Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia," *Thrombosis and Haemostasis*, vol. 82, no. 2, pp. 481–485, 1999.
- [144] M. Murga, O. Fernandez-Capetillo, and G. Tosato, "Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2," *Blood*, vol. 105, no. 5, pp. 1992–1999, 2005.
- [145] P. M. Becker, J. Waltenberger, R. Yachechko et al., "Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability," *Circulation Research*, vol. 96, no. 12, pp. 1257–1265, 2005.
- [146] C. Gu, B. J. Limberg, G. Brian Whitaker et al., "Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165," *Journal of Biological Chemistry*, vol. 277, no. 20, pp. 18069–18076, 2002.
- [147] H. Q. Miao, S. Soker, L. Feiner, J. L. Alonso, J. A. Raper, and M. Klagsbrun, "Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165," *Journal of Cell Biology*, vol. 146, no. 1, pp. 233–242, 1999.
- [148] A. W. Koch, T. Mathivet, B. Larrivée et al., "Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B," *Developmental Cell*, vol. 20, no. 1, pp. 33–46, 2011.
- [149] R. Marlow, M. Binnewies, L. K. Sorensen et al., "Vascular Robo4 restricts proangiogenic VEGF signaling in breast," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 23, pp. 10520–10525, 2010.
- [150] M. Weitzman, E. B. Bayley, and U. P. Naik, "Robo4: a guidance receptor that regulates angiogenesis," *Cell Adhesion & Migration*, vol. 2, no. 4, pp. 220–222, 2008.
- [151] M. Fujiwara, M. Ghazizadeh, and O. Kawanami, "Potential role of the Slit/Robo signal pathway in angiogenesis," *Vascular Medicine*, vol. 11, no. 2, pp. 115–121, 2006.
- [152] C. A. Jones, N. Nishiya, N. R. London et al., "Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity," *Nature Cell Biology*, vol. 11, no. 11, pp. 1325–1331, 2009.
- [153] T. Pepini, E. E. Gorbunova, I. N. Gavrilovskaya, J. E. Mackow, and E. R. Mackow, "Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability," *Journal of Virology*, vol. 84, no. 22, pp. 11929–11936, 2010.

- [154] P. Saharinen and T. V. Petrova, "Molecular regulation of lymphangiogenesis," *Annals of the New York Academy of Sciences*, vol. 1014, pp. 76–87, 2004.
- [155] I. N. Gavrilovskaya, E. E. Gorbunova, and E. R. Mackow, "ANDV infection of lymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and VEGF-C sensitive," *Journal of Virology*. In press.
- [156] J. Lähdevirta, "Clinical features of HFRS in Scandinavia as compared with East Asia," *Scandinavian Journal of Infectious Diseases*, vol. 36, pp. 93–95, 1982.
- [157] A. S. Khan, R. F. Khabbaz, L. R. Armstrong et al., "Hantavirus pulmonary syndrome: the first 100 US cases," *Journal of Infectious Diseases*, vol. 173, no. 6, pp. 1297–1303, 1996.
- [158] T. Krakauer, J. W. Leduc, and H. Krakauer, "Serum levels of tumor necrosis factor- α , interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome," *Viral Immunology*, vol. 8, no. 2, pp. 75–79, 1995.
- [159] I. N. Gavrilovskaya, E. E. Gorbunova, F. Koster, and E. R. Mackow, "Elevated VEGF levels in pulmonary edema fluid and pbmcs from patients with acute hantavirus pulmonary syndrome," In press.
- [160] J. W. Hooper, T. Larsen, D. M. Custer, and C. S. Schmaljohn, "A lethal disease model for hantavirus pulmonary syndrome," *Virology*, vol. 289, no. 1, pp. 6–14, 2001.
- [161] V. Wahl-Jensen, J. Chapman, L. Asher et al., "Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters," *Journal of Virology*, vol. 81, no. 14, pp. 7449–7462, 2007.
- [162] D. Safronetz, M. Zivcec, R. LaCasse et al., "Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus," *PLoS Pathogens*, vol. 7, no. 12, Article ID e1002426, 2011.
- [163] C. B. Jonsson, J. Hooper, and G. Mertz, "Treatment of hantavirus pulmonary syndrome," *Antiviral Research*, vol. 78, no. 1, pp. 162–169, 2008.
- [164] C. A. Jones, N. R. London, H. Chen et al., "Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability," *Nature Medicine*, vol. 14, no. 4, pp. 448–453, 2008.
- [165] Y. Wallez, F. Cand, F. Cruzalegui et al., "Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site," *Oncogene*, vol. 26, no. 7, pp. 1067–1077, 2007.
- [166] Y. Wang, G. Jin, H. Miao, J. Y. S. Li, S. Usami, and S. Chien, "Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 6, pp. 1774–1779, 2006.
- [167] S. Huber, C. J. Bruns, G. Schmid et al., "Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis," *Kidney International*, vol. 71, no. 8, pp. 771–777, 2007.
- [168] D. D. Kim, D. M. Kleinman, T. Kanetaka et al., "Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo," *Microcirculation*, vol. 17, no. 2, pp. 128–136, 2010.
- [169] S. C. Land and A. R. Tee, "Hypoxia-inducible factor 1 α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif," *Journal of Biological Chemistry*, vol. 282, no. 28, pp. 20534–20543, 2007.
- [170] T. L. Phung, K. Ziv, D. Dabydeen et al., "Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin," *Cancer Cell*, vol. 10, no. 2, pp. 159–170, 2006.
- [171] Q. Xue, J. A. Nagy, E. J. Manseau, T. L. Phung, H. F. Dvorak, and L. E. Benjamin, "Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164-Driven Angiogenesis, in Part by Blocking S6Kinase," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 8, pp. 1172–1178, 2009.
- [172] J. R. Teijaro, K. B. Walsh, S. Cahalan et al., "Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection," *Cell*, vol. 146, no. 6, pp. 980–991, 2011.
- [173] G. Schmid, M. Guba, I. Ischenko et al., "The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1," *Journal of Cellular Biochemistry*, vol. 101, no. 1, pp. 259–270, 2007.
- [174] K. Porkka, H. J. Khoury, R. L. Paquette, Y. Matloub, R. Sinha, and J. E. Cortes, "Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion," *Cancer*, vol. 116, no. 2, pp. 377–386, 2010.
- [175] L. M. Acevedo, S. Barillas, S. M. Weis, J. R. Göthert, and D. A. Cheresch, "Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor," *Blood*, vol. 111, no. 5, pp. 2674–2680, 2008.
- [176] D. Xu, M. M. Fuster, R. Lawrence, and J. D. Esko, "Heparan sulfate regulates VEGF165- and VEGF121- mediated vascular hyperpermeability," *Journal of Biological Chemistry*, vol. 286, no. 1, pp. 737–745, 2011.
- [177] V. Brinkmann, "Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology," *Pharmacology and Therapeutics*, vol. 115, no. 1, pp. 84–105, 2007.
- [178] X. Peng, P. M. Hassoun, S. Sammani et al., "Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury," *American Journal of Respiratory and Critical Care Medicine*, vol. 169, no. 11, pp. 1245–1251, 2004.
- [179] T. Sanchez, T. Estrada-Hernandez, J. H. Paik et al., "Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability," *Journal of Biological Chemistry*, vol. 278, no. 47, pp. 47281–47290, 2003.
- [180] R. K. Jain and L. L. Munn, "Leaky vessels? Call ang1," *Nature Medicine*, vol. 6, no. 2, pp. 131–132, 2000.
- [181] L. Pizurki, Z. Zhou, K. Glynnos, C. Roussos, and A. Papapetropoulos, "Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production," *British Journal of Pharmacology*, vol. 139, no. 2, pp. 329–336, 2003.
- [182] S. C. Satchell, K. L. Anderson, and P. W. Mathieson, "Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties," *Journal of the American Society of Nephrology*, vol. 15, no. 3, pp. 566–574, 2004.
- [183] G. Thurston, C. Suri, K. Smith et al., "Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1," *Science*, vol. 286, no. 5449, pp. 2511–2514, 1999.
- [184] B. J. McVerry and J. G. N. Garcia, "In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights," *Cellular Signalling*, vol. 17, no. 2, pp. 131–139, 2005.
- [185] K. Podar, G. Tonon, M. Sattler et al., "The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma,"

- Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 51, pp. 19478–19483, 2006.
- [186] B. J. McVerry, X. Peng, P. M. Hassoun, S. Sammani, B. A. Simon, and J. G. N. Garcia, “Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury,” *American Journal of Respiratory and Critical Care Medicine*, vol. 170, no. 9, pp. 987–993, 2004.
 - [187] M. R. Morgan, M. J. Humphries, and M. D. Bass, “Synergistic control of cell adhesion by integrins and syndecans,” *Nature Reviews Molecular Cell Biology*, vol. 8, no. 12, pp. 957–969, 2007.
 - [188] D. M. Beauvais and A. C. Rapraeger, “Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation,” *Journal of Cell Science*, vol. 123, no. 21, pp. 3796–3807, 2010.
 - [189] M. Schuksz, M. M. Fuster, J. R. Brown et al., “Surfen, a small molecule antagonist of heparan sulfate,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 35, pp. 13075–13080, 2008.
 - [190] A. R. Albig and W. P. Schiemann, “Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells,” *DNA and Cell Biology*, vol. 23, no. 6, pp. 367–379, 2004.
 - [191] L. J. Freeman, A. Lomas, N. Hodson et al., “Accelerated publication fibulin-5 interacts with fibrillin-1 molecules and microfibrils,” *Biochemical Journal*, vol. 388, no. 1, pp. 1–5, 2005.
 - [192] A. Guadall, M. Orriols, R. Rodríguez-Calvo et al., “Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1 α)-dependent mechanism,” *Journal of Biological Chemistry*, vol. 286, no. 9, pp. 7093–7103, 2011.
 - [193] Z. K. Otroock, J. A. Makarem, and A. I. Shamseddine, “Vascular endothelial growth factor family of ligands and receptors: review,” *Blood Cells, Molecules, and Diseases*, vol. 38, no. 3, pp. 258–268, 2007.